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Introduction: Factors relating to the interpersonal relationship between the patient and
their physician and social environment are important components, which contribute to
their response to treatment for major depressive disorder. This study aimed to assess
the influence of optimism, perfectionism, therapeutic alliance, empathy, social support,
and adherence to medication regimen in the response to antidepressant treatments in
the context of normal primary care clinical practice.
Method: We conducted a prospective study in which 24 primary care physicians
administered sertraline or escitalopram to 89 patients diagnosed with major depressive
disorder. The response to treatment and remission of the episode was assessed at 4
and 12 weeks by Cox regression. The effect of adherence to the medication regimen
was assessed by multiple regression statistical techniques.
Results: Adherence to medication (HR = 0.262, 95% CI = 0.125–0.553, p < 0.001)
and patient perfectionism (HR = 0.259, 95% CI = 0.017–0.624, p < 0.01) negatively
predicted the initial response to treatment, whereas patient optimism (HR = 1.221, 95%
CI = 1.080–1.380, p < 0.05) positively predicted it. Patient optimism (HR = 1.247,
95% CI = 1.1–1.4, p < 0.05), empathy perceived by the patient (HR = 1.01,
95% CI = 1001–1002, p < 0.05), and therapeutic alliance (HR = 1.02, 95%
CI = 1001–1.04, p < 0.05) positively predicted episode remission, while patient
perfectionism (HR = 0.219, 95% CI = 0.093–0.515, p < 0.001) and low adherence
to the treatment regimen (HR = 0.293, 95% CI = 0.145–0.595, p < 0.001) negatively
predicted it. Finally, social support (p< 0.01) and therapeutic alliance (p< 0.05) predicted
adherence to the medication regimen.
Conclusions: In addition to taking the antidepressant drug, other factors including the
personal interactions between the patient with their primary care physician and with their
social environment significantly influenced the patients’ initial response and the final rate
of episode remission.
Keywords: antidepressants, optimism, therapeutic alliance, perfectionism, empathy, social support, primary care
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INTRODUCTION
Major depressive disorder is a heterogeneous condition
characterized by a diagnosis of syndromic validity, without
biological specificity. The wide variability of its presentation,
course, and responses to different types of treatments is also
reflected in the diversity of the theoretical explanations of
its etiology, including genetic, biochemical, endocrine and
neurophysiological, psychological, and social factors (1). Still
other theories deny the validity of the diagnosis from a social
perspective (2).
Clinical trials demonstrate the efficacy of drugs in the
treatment of depression (1, 3), and studies using rigorous
meta-analyses suggest that, based on their efficacy and cost,
escitalopram, and sertraline are appropriate choices (4). A recent
meta-analisys by the same author added more information
for optimal treatment (5). However, non-specific responses to
antidepressant pharmacological treatment play an important role
in their efficacy. Indeed, a wide range of drugs with demonstrated
efficacy also show a high rate of response to placebos (6–9), which
has even led some authors to question the use of drugs to treat
mild depression (6).
This non-specific effect reflects the serious importance of
psychological factors in pharmacological treatments, especially
those that entail an interpersonal relationship both inside and
outside of the clinical relationship. In the field of clinical care,
the concept of placebo has often been used to cover several
psychological factors that may be in force in the rendering of
antidepressant effects (10). Unlike spontaneous healing, or that
produced via pharmacological means, the placebo effect is a form
of interpersonal healing (11), which involves both the patient’s
expectations of their reactions to the drug and the context in
which it is administered (12). These factors have led to the study
of how various personality traits influence patient responses
to placebos, and although the results regarding a wide range
of traits such as introversion, intelligence, or self-esteem are
controversial, a clear influence has been demonstrated in the case
of optimism. In this sense, it has been proven that the relationship
between optimism and placebo response is not that of a simple
increase or decrease, but rather, that optimism determines the
response to the placebo by interacting between the context of
the drug administration and the subject’s expectations (13, 14).
Along with optimism, perfectionism is also important in the
response to treatment with antidepressants, especially in terms
of how this personality trait interacts with therapeutic alliance.
Blat and Zuroff (15) showed that perfectionism significantly
influences both psychotherapeutic and pharmacological recovery
via antidepressant-mediated treatment by negatively interfering
with therapeutic alliance.
In this sense, the therapeutic alliance between the patient and
professional at the beginning and throughout the treatment, plays
a fundamental role in the outcome of both pharmacological (16)
and psychotherapeutic (17, 18) treatments. In the specific case
of depression, it is an essential ingredient which is common to
the different types of psychotherapy used to treat depression,
the placebo effect, and the combination of psychotherapy and
pharmacotherapy (19, 20). In pharmacological studies, the
effect of therapeutic alliance has always been attributed to
its impact on treatment-regimen adherence, specifically to its
determining influence on incorrect or insufficient medication
use (21). In studies investigating the effect of psychotherapy, in
addition to improving adherence, treatment alliance directly and
independently influences the outcome of cases with a wide range
of diagnoses, populations, and psychotherapy types (17, 22), and
this effect increases in relation to the quality of the treatment (18).
The definitions of therapeutic alliance have varied from their
initial formulation by Freud (23) to evolve into a concept, which
is more universally accepted by various theoretical disciplines.
The common factor is an emphasis on collaboration and
consensus between the professional and the patient, which is
built based on three components: agreement on the therapeutic
goals, consensus on the tasks to be performed in the therapy,
and the link between the therapist and the patient (24, 25).
Several meta-analyses carried out in recent years (17, 18, 22)
have coincided in pointing out that therapeutic alliance has
a general effect on the outcome of both introspection-based
and structured psychotherapies. However, distinction between
the three dimensions of therapeutic alliance is important
in structured psychotherapy modalities such as cognitive-
behavioral therapies. This is because these therapy types
emphasize the use of specific techniques and the alliance
components, based on their goals and tasks, are more important
than in less structured psychotherapies (26).
Because one of the basic components of therapeutic alliance
is the emotional bond between the professional and the patient
(24, 27), which is favored by mutual understanding (27) or
a warm relationship of high regard and respect (28), the
ability of the professional to develop and maintain an empathic
attitude toward their patient is a fundamental factor in the
development of a therapeutic alliance link (29–31) and in
its potential influence on the antidepressant pharmacological
response. Similarly, among the interpersonal relationship factors
that are predictive of a response to antidepressant drugs, social
support also stands out in the external field of clinical care (32),
given that scarce social support is a risk factor in both the etiology
and recurrence of depressive episodes and also in the response to
pharmacological treatment (33, 34).
The aim of this study was to investigate the role that the
aforementioned psychological factors play in the outcome of
antidepressant treatments. Given that antidepressants are mainly
prescribed in primary care, we undertook this research in these
settings, via family general primary-care physicians (GPs) during




The study was approved by the ethics committee at Hospital
Arnau de Vilanova-Paterna Health Centre and all the patients
signed their informed consent; 24 general primary-care
physicians (GPs) from the Paterna Health Centre (Spain)
participated in the study (mean years of age = 43; mean years
working = 21). The Centre has a ratio of 1,680 patients by
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GP, similar to the rest of the health centers of the Valencian
Community and other contexts of the National Health System in
Spain. The GPs in the study cover a population of 36,000 adults
between 15 and 60 years of age. In the Valencian Community the
average of visits to the GP is 4.2 by person year, and 5.7 visits by
patient year. In our study, the incidence of depression in primary
care associated with the prescription of antidepressants is 4,16
cases by 1,000 patient year, similar, although slightly inferior, to
other countries where the figures are between 5 and 10 cases per
1,000 patient year (35).
Patients who were consecutively attended to in the Paterna
Health Centre were prospectively selected by their GPs over 12
months during the course of their everyday work. The GPs were
asked to select patients with a suspected diagnosis of an episode
of major depressive disorder according to their clinical criteria.
During the first consultation, the GP provided the patient with
information about the disorder but refrained from prescribing
treatment and instead arranged a second consultation with them
in the following week. At the second consultation, the GPs used
the Spanish version of the Patient Health Questionnaire-9 [PHQ-
9; (36, 37)], and based on the results, selected patients aged
between 18 and 60 years whose PHQ-9 score was equal to or
>15. These patients were invited to participate in the study
and if they agreed to so do, signed the informed consent form.
Those suffering from dementia, bipolar disorder, psychosis, or
substance related disorders, as well as those who had less than
12 years’ schooling or who were not able to understand the
informed consent form or the tests, were excluded. Following
the latest update of the literature at the time of the study (5),
the GPs established treatment with sertraline (100 mg/day) or
escitalopram (20 mg/day) at their discretion and referred the
patient for diagnostic confirmation and baseline and follow-up
evaluations. The GPs continued to attend to their patients by
setting an appointment for the initial follow-up review of the
treatment at 4 weeks and undertaking a second follow-up at 12
weeks.Within a period not exceeding 48 h after the GP prescribed
the treatment, a psychiatrist confirmed the diagnosis, and a team
of two psychiatric nurses trained in the use of the appropriate
instruments evaluated the predictive variables. This team was
based in a Mental Health Centre adjacent to the Primary Care
Centre in Paterna.
Assessment
The diagnosis was confirmed by using the Spanish version of
the Structured Clinical Interview for the Fourth Diagnostic
and Statistical Manual of Mental Disorders (DSM-IV) Axis-I
Disorders [SCID-I; (38–40)]. Patients who did not meet the
SCID-I diagnostic criteria for major depressive disorder were
excluded from this study. Those whomet the criteria were further
assessed, using the procedure and instruments described below.
The PHQ-9 was not only used as a screening tool, it was
also employed to decide the outcome variables by evaluating
the early response and the clinically-significant improvement
in these patients. This questionnaire comprises 9 items derived
from the DSM-IV. Its reliability and validity have been proven
in different Spanish-speaking countries, both in primary and
specialized care (36, 41–43), including when implemented as a
telephone interview (42). The threshold for detecting an early
response to treatment was established as a reduction of five points
between the baseline score and the score at 4 weeks (44–47). At
12 weeks, the clinically-significant improvement was assessed by
a 50% decrease the score with respect to the initial evaluation and
a score lower than 10 (44–47).
The main difficulty in exploring the patient’s evaluation of
their GP’s attitudes is the strong bias caused by conformism,
or social desirability, and impression management. To avoid
this problem, GPs’ empathy, as perceived by the patients, was
assessed using the Repertory Grid Technique [RGT; (48, 49)].
Unlike self-report assessments that only detect explicit attitudes,
the RGT also allows assessment of implicit attitudes and is
a tool that has been successfully used in a wide variety of
contexts (50, 51). For this study a grid of eight elements and
five constructs was prepared. The names of the eight most
important people in the patient’s life were chosen as elements.
Following Karkuff’s definition of empathy (52), the subsequent
sentences referring to the GP’s attitudes were used as constructs:
“They strive to understand me,” “They understand what I mean,”
“They comprehend how I feel,” “They understand me even if I
cannot express myself properly,” and “I like my GP”. Empathy
scores were obtained by summing the Spearman coefficients
of correlation for “I like my GP” and each of the other four
constructs.
The therapeutic alliance, as evaluated by the patient, was
measured using the Spanish version of the Working Alliance
Theory of Change Inventory [WATOCI; (53)]. The WATOCI is
based on 17 questions scored on a Likert scale and assesses the
degree of agreement between the GP and the patient in terms
of the objectives and tasks of the treatment and in the existence
of a positive GP–patient understanding (54). The reliability and
validity of the Spanish version has been deemed acceptable (55).
Social support was assessed using the Spanish version (56) of
the Duke-UNC-11 Social Support Questionnaire (57). This scale
evaluates “confidential support” (the availability of people whom
the patient can communicate with) and the “emotional support”
(demonstrations of love, affection, and empathy) available to the
patient. Its test-retest reliability has been verified for both the
English and Spanish versions, with scores of 0.9 and 0.8 for
the self-administered and professionally-administered versions,
respectively. In addition, the validity of the Spanish version has
been proven in the contexts of different socioeconomic levels
(56, 58). In our study we used a global measure of social support
by summing the scores of these scale items.
The optimism trait was measured using the 10-item Revised
Life Orientation Test [LOT-R; (59)]. These items, three
for optimism, three for pessimism, and four neutral, are
measured on a Likert scale. A single score is obtained by
summing the optimism item scores and the inverted pessimism
scores. We used the Spanish version, which demonstrated
similar psychometric characteristics and validity to the original
scale (60).
Perfectionism was measured with the perfectionism subscale
(61) from the Dysfunctional Attitude Scale [DAS; (62)]. The DAS
is a 40-item instrument that expresses cognitive vulnerability to
depression and which has shown high reliability and validity
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(62, 63). Imber (61) revealed that the scale consists of two
fundamental factors called perfectionism and need for approval.
This distinction has subsequently been validated with other
factorial analyses in other samples and has shown good internal
consistency and test-retest reliability (61, 62, 64, 65). For this
study, the perfectionism subscale was used, considering the
total score and the summary in two categories, and defining
perfectionists as patients who obtained a score more than one
standard deviation higher than the average.
Adherence to the treatment regimen was measured using
the Spanish version of the self-reported Morisky Medication
Adherence Scale [MMAS-4; (66, 67)]. This scale, which can
easily be integrated into clinical consultations, contains four
dichotomous items that measure the failure to take medication
by evaluating the possible difficulties the patient may refer to, and
is scored by summing the items so that the higher the score the
greater the non-compliance. Concurrent and predictive validity
has shown for the MMAS-4, and it has also been used to evaluate
adherence to antidepressant medication in primary care (68, 69).
The SCID-I, PHQ-9, and MMAS-4 scales were all
administered at the patient follow-up evaluations.
Statistical Analysis
To analyse the early response and clinically-significant
improvement, a Cox regression model was used. As independent
variables, the PHQ-9 score was introduced in the first evaluation
(to control for the possible confounding effect of the severity
of the episode), along with adherence to treatment, empathy,
optimism, social support, perfectionism, therapeutic alliance.
As the outcome variables, measures of therapeutic change,
early response, and clinically-significant improvement were
introduced. The outcome variables were analyzed by projecting
forward the last observation in the group of patients who agreed
to participate in the study and who presented at least one
observation after the baseline assessment. To analyse adherence
to the medication regimen, we used a multiple regression
model in which the same variables indicated above were used as
independent variables along with the MMAS-4 score result as a
dependent variable.
RESULTS
The 24 GPs (mean age = 43 years; mean years of working = 21)
who participated in the study identified 147 patients with a
possible diagnosis of major depressive disorder who were seen
consecutively at the Paterna Health Centre over a period of 1
year. Of these, 128 patients presented a PHQ-9 score higher than
15; 39 declined to be included or did not meet the criteria for
major depressive disorder or participation in the study, and 89
were finally included; 7% were lost to follow-up (Figure 1). The
mean age was 42 years [standard deviation (SD) = 13] and the
average level of education was 10 years (SD= 3) of schooling. At
the baseline assessment, there were no differences between men
and women for any of the variables and there were no significant
results in the measurements of response or remission with
respect to gender, age, civil status or education-level variables
of the patients, nor any of the sociodemographic variables of
FIGURE 1 | Flow of the patients through the study. GP, General Primary Care
Physician; PHQ-9, Patient Health Questionnaire; MMD, Major Depressive
Disorder; RGT, Repertory Grid Technique, WATOCI, Working Alliance Theory of
Change Inventory; DUKE-UNC, Duke’s Social Support Questionnaire, LOT-R,
Revised Life Orientation Test; DAS, Disfunctional Attitude Scale; MMAS-4
Morisky Medication Adherence Scale.
the GPs (sex, age, or number of years of working). Sertraline
was given to 40 (45%) participants and escitalopram was given
to 58 (65%) participants. Sertraline did not show statistical
differences with respect to escitalopram in the remission or
response measurements. No adverse effects due to medication
were reported.
Assessment of the early response at 4 weeks (as measured
by a decrease in the initial PHQ-9 score of more than five
points in the first 6-week interval), indicated that 46 subjects
(55.4%) had responded to treatment vs. 37 (44.6%) who had
not responded. Of the patients who responded, 7 (15%) did
not showed clinically significant improvement. Additionally, 7
(18%) of the patients who did not present an early response,
later responded to the treatment. Optimism showed a higher
probability of being associated with an early response at 4 weeks
(Hazard Ratio [HR] = 1.221, 95% CI = 1.080–1.380, p < 0.05),
while perfectionism (HR = 0.259, 95% CI = 0.107–0.624,
p < 0.01) and adherence (HR = 0.262, 95% CI = 0.125–0.553,
p < 0.001) were negatively associated with the probability of a
response. The influence of empathy on social support was not
significant, although the effect of therapeutic alliance was near
to statistical significance (Table 1).
Regarding clinically-significant improvement at 12 weeks,
optimism was associated with a 25% higher probability of
remission for each unit increase on the PHQ-9 scale (HR =
1.247, 95% CI = 1.1–1.4, p < 0.05). The empathy perceived by
the patient (HR = 1.01, 95% CI = 1.001–1.02, p < 0.05) and
the therapeutic alliance (HR = 1.02, 95% CI = 1.04–1.001) also
had a significant effect on the therapeutic outcome at 12 weeks.
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TABLE 1 | Cox regression model of early response to antidepressant treatment.
Hazard
ratio
Sig. 95% CI for Exp(B)
Upper Lower
Social support 0.972 0.108 0.940 1.006
Optimism 1.221 0.001 1.080 1.380
Therapeutic alliance 1.017 0.074 1.037 0.998
Empathy 1.008 0.207 0.996 1.020
Perfectionism 0.259 0.003 0.107 0.624
Adherence to the medication regimen* 0.262 0.000 0.125 0.553
Difference basal phq – first control > 5. *Morisky–Green in the first evaluation.
Perfectionism had a negative influence, meaning that being a
perfectionist produced a 4.5-fold increase in the risk that the
episode would not subside (HR = 0.219, 95% CI = 0.093–0.515,
p < 0.001). Similarly, low adherence to the treatment regimen
increased the risk that the episode did not improve by 3.4-fold
for each unit increase on the PHQ-9 scale (Table 2).
Regarding adherence, 72% of the patients did not show
any obstacles, or difficulties, to taking their medication,
19.5% had one, and 8.5% had two or more obstacles. There
were no differences in the initial severity of the depressive
episode, as measured with the PHQ-9 scale, between patients
who did or did not abandon their medication regimen
(mean abandonment = 20.2, SD = 2.2 vs. mean non-
abandonment = 21.7, SD = 2.8; t = −1.8; not significant). As
shown in Table 3, the multiple regression model analysis showed
that therapeutic alliance and social support predicted medication
regimen adherence (model R2 = 0.25, f = 3.1, p < 0.05). None
of the other variables were significant. Gender, marital status, and
being on sick leave from work did not have any significant effect
on any of the treatment response variables or patient adherence
to their medication regimen.
DISCUSSION
The most notable result of this present study is that, both the
therapeutic alliance and the empathy perceived by patients from
their GPs before starting antidepressant treatment for major
depression, significantly predict the result of this treatment,
regardless of the effect of their compliance to the medication
regimen. We also found that the therapeutic outcome is
positively predicted by optimism and negatively predicted by
perfectionism. This present study explored these factors within
the context and conditions of normal primary care clinical
practice. Most patients with major depressive disorder are treated
within this context (70, 71) but few studies have been performed
in this area regarding the influence of optimism, perfectionism,
treatment alliance, and empathy, which are all frequently studied
in other fields, including in psychotherapy.
It is important to consider that the treatment alliance and
empathy perceived by the patient during the studymay have been
considerably favored by the development of a GP–patient rapport
during prior consultations. However, in this study these two
TABLE 2 | Cox regression model of clinically-significant improvement considering
a decrease ≥50% in the initial score.
Hazard
ratio
Sig. 95.0% CI for Exp(B)
Upper Lower
Social support 0.980 0.247 0.947 1.014
Optimism 1.247 0.000 1.102 1.411
Therapeutic alliance 1.020 0.039 1.040 1.001
Empathy 1.013 0.035 1.001 1.025
Perfectionism 0.219 0.000 0.093 0.515
Adherence to the medication regimen* 0.293 0.001 0.145 0.595
*Morisky–Green sum of all evaluations.
TABLE 3 | Linear regression model predicting adherence (non-compliance of
medication).
B t Sig.
(Constant) 1.392 2.084 0.043
Social support −0.025 −2.873 0.006
Optimism 0.038 1.372 0.177
Therapeutic alliance −0.012 −2.522 0.015
Perfectionism 0.166 0.679 0.501
Empathy 0.002 0.611 0.544
R2 of the model = 0.25, f = 3.1, p < 0.05.
factors were assessed only after two consultations had occurred:
the depression was evaluated at the first and the medication
was prescribed in the second—both before any pharmacological
effects could have developed. The temporal precedence between
the predictive variables and the results are a crucial condition,
thus, given that we met this condition in this study, we can
state that our results have high ecological validity and that
the direction of the effect is attributable to these variables,
independently of the patient’s therapeutic regimen adherence.
Our initial hypothesis was that factors related to the personal
interaction between the patient and their GP, influence the
patient’s initial response and their clinically-significant response
to treatment, independently of the pharmacological effect. This
hypothesis has been corroborated regarding some factors directly
related to the GP–patient relationship, although these elements
do not all simultaneously exert the same influence. However,
outside of this clinical interaction, social support has been shown
to influence patient adherence with the medication regimen,
specifically in terms of non-compliance.
Both optimism and perfectionism predicted an early response
to treatment at 4 weeks and a clinically-significant improvement
at 12 weeks. It is important to remember that this was a
naturalistic study which evaluated the patients’ responses to the
prescription of an antidepressant drug by their GP. However, the
effects of this intervention are not only rendered by the specific
pharmacological effects of the drug administered, but also by a
set of actions and interactions between the GP and the patient.
This produces a complexmixture of processes in which the choice
Frontiers in Psychiatry | www.frontiersin.org 5 September 2018 | Volume 9 | Article 416
Salazar-Fraile et al. Interpersonal Factors Predict Antidepresant Treatment
of drug and its dosage, as well as the GP–patient assessments,
agreements, expectations, and attributions all interact in ways
which can affect the treatment outcome.
Although our study does not identify any of the mechanisms
by which optimism could exert an influence on the therapeutic
outcome, optimistic subjects tend to ignore or minimize the
contradictions between the expectations of an experience and
the experience itself. Thus, in our context, subjects with high
levels of optimism who notice an initial change after undergoing
an antidepressant drug treatment would likely increase their
expectations of improvement, in so facilitating their own
response to the prescription (14, 72). Regarding the clinically-
significant improvement at 12 weeks, optimistic people tend
to more frequently practice healthy behaviors than their non-
optimistic counterparts (73), and in addition, optimists tend to
have a greater capacity for adaptation and flexibility of thought
(74); these abilities mean that these patients would have a greater
likelihood of remission from depressive episodes (75).
Perfectionism significantly reduces the outcome of
antidepressant and psychotherapeutic treatments, either
directly or by conditioning the therapeutic alliance (15, 76, 77).
Subjects with high levels of perfectionism tend to find that the
degree of change after a therapeutic intervention is insufficient
or low; they are more prone to experience dissatisfaction,
disappointment, and despair regarding the therapeutic alliance
(78) and would cause their therapeutic response to diminish.
In contrast, optimism has been shown to reduce the negative
consequences of pessimism (79). Optimism guides the focus of
attention toward a satisfactory goal; thus, this trait would aid
perfectionist subjects in focusing on their improvement, helping
them to avoid focusing their attention on censorship or the
disappointment of a poorer therapeutic response than they had
expected.
Our results indicate that, in addition to the factors that
act in the early-response phase, other elements are involved
in the clinically-significant response phase. The therapeutic
alliance would have a direct influence, and while empathy would
also play a significant role as a component of the therapeutic
alliance, this trait would be independent from it. It is probable
that factors implicated in the therapeutic alliance (24, 25)
play a more important role in this second phase. These may
include elements related to greater specification of the exact
causes of the patient’s depression and agreement that certain
actions could contribute to the process of resolving the episode.
Because the therapeutic alliance is also based on the GP–patient
bond, empathy can significantly contribute by generating an
environment of support, acceptance, and collaboration, and
therefore produce a higher-quality relationship. In addition,
empathy also favors the expression of feelings and thoughts (80),
thereby helping to clarify problems or conflicts related to the
depressive episode.
It is important to consider that in clinical approaches to the
administration of a drug, prescription of the drug alone is not
usually sufficient for the patient’s recovery (81, 82). The process
not only involves the prescription, but also the application of
procedures to encourage the patient to take the medication and
to reassure them about its side effects or inconveniences. These
patients also require advice and information about the evolution
and prognosis of the disorder. This requires a “minimum
therapeutic support condition” (82) like those shared by different
psychotherapies for depression—especially the formation of
a good therapeutic alliance. Providing a warm therapeutic
relationship, a rational explanation about the disease symptoms,
and a plan for its treatment help reduce the patient’s potential
feelings of anguish or demoralization about their condition.
Acceptance of pharmacological treatment can be favored by a
collaborative environment in which the patient agrees with the
doctor that the medication will contribute to improving their
depression.
Moreover, an environment of social support can help
to resolve and overcome some factors that may lead to
the abandonment of medication regimens, such as fear of
dependence, difficulty in tolerating the side effects, or lack of
the expected response during the first few days. Evidence of the
relationship between social support and adherence to treatment
regimens has been confirmed by multiple studies and meta-
analyses (83). Along with pharmacotherapy and psychotherapy,
social support is an important part of treating depression
(1). Additionally, in agreement with other studies (84), our
results show that social support also influences compliance
with antidepressant medication regimens. Guidelines for clinical
use indicate that to improve adherence to treatment regimens,
clinicians must consider that patients with depression may
be unmotivated, pessimistic about their treatment, neglect to
properly care for themselves, or suffer from memory problems—
all factors that good social support can help to compensate for.
Although the processes which influence this effect are unproven,
social support acts as a buffer to stress by influencing behavior,
favoring adaptive behaviors, facilitating the internalization of
norms, and administering sanctions for non-health-oriented
behaviors (83). Likewise, the absence of a social support network
can interfere with healthy habits, limiting the patient’s time and
energy, motivation, self-control, confidence, self-esteem, and the
management of emotional conflicts.
It is probable that different elements of therapeutic alliance
intervene in this second phase. These may include greater
specification of the exact causes of the patient’s depression, the
agreement that certain actions can contribute to resolving the
process, as well as a link between the professional and the
patient. Our study highlights the significant correlation between
the lack of adherence to treatment regimens and the three
different factors of the alliance, specifically, with agreement on
the goals and causes (r = −0.35, p < 0.01), tasks and actions
(r = −0.34, p < 0.01), and the GP–patient emotional bond
(r = −0.29, p < 0.05). Other types of support from other
areas, such as instrumental social support (e.g., helping to do
something or solving social problems), financial support, or
the extent and frequency of social network contact, are likely
to significantly affect the evolution of the depressive episode.
However, these factors are beyond the scope of this study which
focused only on the response to treatment with antidepressant
drugs administered via primary-care GPs.
This study was carried out in a single health center, limiting
the generalization of the final results. Nevertheless, the figures of
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incidence ratios and the sociodemographic characteristics of the
population attended to, suggest that this center is similar to other
centers of the Valencian Community and Spain. Further multi-
center studies with larger samples of patients and GPs are needed
to validate these results. The results cannot be generalized in
patients who are suffering from depression and are not identified
or treated by GPs. Our results can only be applied to the daily
practice of GPs once they have identified and decided to treat
a patient. There could also exist an association between the
predictive variables and the identification and treatment of the
episode. This must be solved in future studies that could clarify
whether optimism, perfectionism, alliance, social support and
empathy influence the detection and the decision of treating a
depressive episode.
We were not able to study whether the predictor variables
interact with each other as episodes evolve because these were
only recorded at the baseline assessment. Using larger samples
in future research would allow different trait subtypes, especially
perfectionism, to be distinguished within some variables, and
would also allow the influence of different factors, such as
alliance, empathy, or social support to be differentiated. This
would help to guide specific interventions which could be
adjusted to suit the characteristics of each patient. New studies
with an experimental design which incorporates a wider variety
of drugs would help to further elucidate the probable causal
relationship between the variables studied, as well as the role
of factors common to the process of prescribing antidepressant
drugs.
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